CA2994180A1 - Methods for the modulation of lgals3bp to treat systemic lupus erythematosus - Google Patents

Methods for the modulation of lgals3bp to treat systemic lupus erythematosus Download PDF

Info

Publication number
CA2994180A1
CA2994180A1 CA2994180A CA2994180A CA2994180A1 CA 2994180 A1 CA2994180 A1 CA 2994180A1 CA 2994180 A CA2994180 A CA 2994180A CA 2994180 A CA2994180 A CA 2994180A CA 2994180 A1 CA2994180 A1 CA 2994180A1
Authority
CA
Canada
Prior art keywords
lgals3bp
patient
cells
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2994180A
Other languages
English (en)
French (fr)
Inventor
Julie DEMARTINO
Jonathan DERRY
Jaromir Vlach
Nuruddeen LEWIS
Melinda GENEST
Shinji OKITSU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA2994180A1 publication Critical patent/CA2994180A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2994180A 2015-08-31 2016-08-30 Methods for the modulation of lgals3bp to treat systemic lupus erythematosus Abandoned CA2994180A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562212163P 2015-08-31 2015-08-31
US62/212,163 2015-08-31
PCT/US2016/049378 WO2017040464A1 (en) 2015-08-31 2016-08-30 Methods for the modulation of lgals3bp to treat systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
CA2994180A1 true CA2994180A1 (en) 2017-03-09

Family

ID=56883878

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2994180A Abandoned CA2994180A1 (en) 2015-08-31 2016-08-30 Methods for the modulation of lgals3bp to treat systemic lupus erythematosus

Country Status (9)

Country Link
US (1) US20180251559A1 (https=)
EP (1) EP3344283A1 (https=)
JP (2) JP2018526443A (https=)
CN (1) CN107921112A (https=)
AU (1) AU2016317768A1 (https=)
CA (1) CA2994180A1 (https=)
HK (1) HK1252815A1 (https=)
IL (1) IL257755A (https=)
WO (1) WO2017040464A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156448A1 (en) * 2017-02-21 2018-08-30 The Board Of Regents Of The Uiversity Of Texas System Prediction and treatment of immunotherapeutic toxicity
KR101946884B1 (ko) * 2017-04-25 2019-02-13 고려대학교 산학협력단 대사체 분석을 이용한 베체트병의 진단방법
KR102704018B1 (ko) * 2020-06-30 2024-09-06 재단법인 아산사회복지재단 Lgals3bp에 특이적으로 결합하는 항체 및 이의 용도
EP4174086A4 (en) * 2020-06-30 2024-07-24 The Asan Foundation ANTIBODIES SPECIFICALLY BINDING TO LGALS3BP AND USE THEREOF
EP4318629A4 (en) 2021-03-24 2025-11-12 Agc Inc Primer for energy storage device electrodes, primer layer formation composition, electrode for energy storage devices, and secondary battery
IL308044A (en) * 2021-05-04 2023-12-01 Novartis Ag Treatment of systemic lupus erythematosus using antibuffer antibodies
WO2025075163A1 (ja) * 2023-10-04 2025-04-10 国立大学法人東北大学 自己反応性ｄｎ２ｂ細胞が産生する自己抗体およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1247472A (zh) * 1997-01-10 2000-03-15 拜奥根有限公司 用抗cd40l化合物治疗狼疮性肾炎
EP1455813B1 (en) * 2001-12-18 2015-07-15 mondoBIOTECH AG Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis
US8163896B1 (en) * 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
ES2244270A1 (es) * 2003-01-31 2005-12-01 Pilar Universidad Autonoma De Madrid Nueva estrategia de regulacion inmune fundamentada en la molecula inducible durante la activacion leucocitaria cd69.
WO2004076682A2 (en) * 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
WO2011119185A1 (en) * 2010-03-26 2011-09-29 La Jolla Institute For Allergy And Immunology Methods of inhibiting inflammation and inflammatory diseases using gal-3bp (btbd17b, lgals3bp, galectin-3 binding protein, mac-2 binding protein)
US20130052198A1 (en) * 2010-03-29 2013-02-28 The General Hospital Corporation Anti-inflammatory factors
WO2012074396A1 (en) * 2010-11-30 2012-06-07 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle

Also Published As

Publication number Publication date
JP2018526443A (ja) 2018-09-13
EP3344283A1 (en) 2018-07-11
IL257755A (en) 2018-04-30
WO2017040464A1 (en) 2017-03-09
HK1252815A1 (zh) 2019-06-06
AU2016317768A1 (en) 2018-02-22
JP2021050217A (ja) 2021-04-01
US20180251559A1 (en) 2018-09-06
CN107921112A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
US20180251559A1 (en) Methods for the Modulation of LGALS3BP to Treat Systemic Lupus Erythematosus
US10874725B2 (en) Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
Duffy et al. The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis
Coppo et al. Innate immunity and IgA nephropathy
Pitsch et al. CD8+ T‐lymphocyte–driven limbic encephalitis results in temporal lobe epilepsy
US12397037B2 (en) Methods and compositions for immunomodulation
US20220062320A1 (en) Preventing and treating amyloid- beta deposition by stimulation of innate immunity
JP2016035474A (ja) 炎症および自己免疫疾患を治療するための組成物および方法
Yu et al. Therapeutic potential of experimental autoimmune encephalomyelitis by Fasudil, a Rho kinase inhibitor
JP6093304B2 (ja) 神経障害を治療するための免疫原性組成物及び方法
Joosten et al. Induction of tolerance with intranasal administration of human cartilage gp‐39 in DBA/1 mice: Amelioration of clinical, histologic, and radiologic signs of type II collagen–induced arthritis
JP5885923B2 (ja) 免疫応答を低減して免疫状態を治療する方法
Summers et al. Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis
Gushchina et al. Alleviation of neuropathic pain by over‐expressing a soluble colony‐stimulating factor 1 receptor to suppress microgliosis and macrophage accumulation
Singh et al. Tuning immune suppression in systemic autoimmunity with self-derived peptides
Akhtaria et al. Immunopathogenesis of systemic lupus erythematosus
Gushchina et al. Alleviation of neuropathic pain by over-expressing a soluble colony-stimulating factor 1 receptor
John Increased plasma cell differentiation, hyper-responsiveness to TLR9, and loss of peripheral B cell tolerance in mice lacking the transcription factor Ets-1.
JP2002521344A (ja) 免疫疾患におけるＨＣｇｐ−３９の使用
Ishikawa et al. Research Article Systemic Administration of Proteoglycan Protects BALB/c Retired Breeder Mice from Experimental Arthritis
Duivenvoorde et al. Immunomodulation with OCH-pulsed dendritic cells attenuates atherosclerosis
Ryan Mast cells: Activation, location, and function during experimental allergic encephalomyelitis
Schalks Chronic meningeal inflammation as a cause of cortical grey matter pathology in multiple sclerosis
JP2017071615A (ja) 神経障害を治療するための免疫原性組成物及び方法
WO2010024432A1 (ja) 中枢神経損傷治療剤

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20221122